Cargando…
HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD
BACKGROUND: Paediatric High Grade Gliomas (HGG) have poor outcomes with conventional treatment. HGG in association with constitutional DNA mismatch repair deficiency (CMMRD) are hypermutated and have shown dramatic response to checkpoint inhibitors. Salvage following progression or failure to respon...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165311/ http://dx.doi.org/10.1093/neuonc/noac079.247 |
_version_ | 1784720364037734400 |
---|---|
author | Hegde, Kriti Dahl, Christine Depani, Sarita Hargrave, Darren Oostveen, Minou Aguirregomezcorta, Fernando Jeelani, Owase Aquilina, Kristian Gains, Jenny Ching, Yen Jacues, Thomas Merve, Ashirwad Chalker, Jane Addy, Dilys Ahmed, Saira W Yasin, Shireen Mankad, Kshitij Carney, Olivia Sudhakar, Sniya D'Arco, Felice Loebel, Ulrike Jorgensen, Mette |
author_facet | Hegde, Kriti Dahl, Christine Depani, Sarita Hargrave, Darren Oostveen, Minou Aguirregomezcorta, Fernando Jeelani, Owase Aquilina, Kristian Gains, Jenny Ching, Yen Jacues, Thomas Merve, Ashirwad Chalker, Jane Addy, Dilys Ahmed, Saira W Yasin, Shireen Mankad, Kshitij Carney, Olivia Sudhakar, Sniya D'Arco, Felice Loebel, Ulrike Jorgensen, Mette |
author_sort | Hegde, Kriti |
collection | PubMed |
description | BACKGROUND: Paediatric High Grade Gliomas (HGG) have poor outcomes with conventional treatment. HGG in association with constitutional DNA mismatch repair deficiency (CMMRD) are hypermutated and have shown dramatic response to checkpoint inhibitors. Salvage following progression or failure to respond to check point inhibitors has rarely been reported. We describe a successful alternative therapeutic approach targeting the activated pathway (mTOR) in a hypermutated HGG. CASE SUMMARY: A 6-year-old girl presenting with seizures was diagnosed with left frontal lobe HGG with concurrent neck mass (Pilomatrixoma). Presence of synchronous tumours raised the possibility of cancer predisposition; the HGG was hypermutated with germline PMS2 mutation confirming diagnosis of CMMRD. Near total resection was undertaken followed by focal radiotherapy 54 Gy, with 1 cycle of concomitant CCNU. MRI post radiotherapy showed tumour progression. Anti-PDl inhibitor Nivolumab was commenced. CTLA-4 antibody, Ipilimumab was added after 4 cycles of Nivolumab due to poor response. Tumour response was seen, but dual therapy had to be discontinued due to toxicity. The tumour progressed following further single agent Nivolumab. In view of multiple mutations in the mTOR pathway (NF1, PIK3/PTEN, TSC1, TSC2), a mTOR inhibitor, Everolimus was commenced. There was 25% tumour reduction after 4 weeks treatment and further reduction after 6 months. Resection of residual tumour showed necrotic tissue only. There continues to be a sustained response to Everolimus for over 12 months. DISCUSSION: Approximately a third of CMMRD HGG respond to checkpoint inhibitors. For those that don’t, these hypermutated tumours offers the possibility of targeting specific molecular pathways. Response to Everolimus in HGG harbouring mTOR aberrations have been described. To our knowledge this is the first report of successful use of mTOR inhibitor in CMMRD HGG. CONCLUSION: Targeted molecular treatment for patients with CMMRD hypermutated brain tumours should be considered according to the mutated pathways. |
format | Online Article Text |
id | pubmed-9165311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91653112022-06-06 HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD Hegde, Kriti Dahl, Christine Depani, Sarita Hargrave, Darren Oostveen, Minou Aguirregomezcorta, Fernando Jeelani, Owase Aquilina, Kristian Gains, Jenny Ching, Yen Jacues, Thomas Merve, Ashirwad Chalker, Jane Addy, Dilys Ahmed, Saira W Yasin, Shireen Mankad, Kshitij Carney, Olivia Sudhakar, Sniya D'Arco, Felice Loebel, Ulrike Jorgensen, Mette Neuro Oncol High Grade Glioma BACKGROUND: Paediatric High Grade Gliomas (HGG) have poor outcomes with conventional treatment. HGG in association with constitutional DNA mismatch repair deficiency (CMMRD) are hypermutated and have shown dramatic response to checkpoint inhibitors. Salvage following progression or failure to respond to check point inhibitors has rarely been reported. We describe a successful alternative therapeutic approach targeting the activated pathway (mTOR) in a hypermutated HGG. CASE SUMMARY: A 6-year-old girl presenting with seizures was diagnosed with left frontal lobe HGG with concurrent neck mass (Pilomatrixoma). Presence of synchronous tumours raised the possibility of cancer predisposition; the HGG was hypermutated with germline PMS2 mutation confirming diagnosis of CMMRD. Near total resection was undertaken followed by focal radiotherapy 54 Gy, with 1 cycle of concomitant CCNU. MRI post radiotherapy showed tumour progression. Anti-PDl inhibitor Nivolumab was commenced. CTLA-4 antibody, Ipilimumab was added after 4 cycles of Nivolumab due to poor response. Tumour response was seen, but dual therapy had to be discontinued due to toxicity. The tumour progressed following further single agent Nivolumab. In view of multiple mutations in the mTOR pathway (NF1, PIK3/PTEN, TSC1, TSC2), a mTOR inhibitor, Everolimus was commenced. There was 25% tumour reduction after 4 weeks treatment and further reduction after 6 months. Resection of residual tumour showed necrotic tissue only. There continues to be a sustained response to Everolimus for over 12 months. DISCUSSION: Approximately a third of CMMRD HGG respond to checkpoint inhibitors. For those that don’t, these hypermutated tumours offers the possibility of targeting specific molecular pathways. Response to Everolimus in HGG harbouring mTOR aberrations have been described. To our knowledge this is the first report of successful use of mTOR inhibitor in CMMRD HGG. CONCLUSION: Targeted molecular treatment for patients with CMMRD hypermutated brain tumours should be considered according to the mutated pathways. Oxford University Press 2022-06-03 /pmc/articles/PMC9165311/ http://dx.doi.org/10.1093/neuonc/noac079.247 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | High Grade Glioma Hegde, Kriti Dahl, Christine Depani, Sarita Hargrave, Darren Oostveen, Minou Aguirregomezcorta, Fernando Jeelani, Owase Aquilina, Kristian Gains, Jenny Ching, Yen Jacues, Thomas Merve, Ashirwad Chalker, Jane Addy, Dilys Ahmed, Saira W Yasin, Shireen Mankad, Kshitij Carney, Olivia Sudhakar, Sniya D'Arco, Felice Loebel, Ulrike Jorgensen, Mette HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD |
title | HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD |
title_full | HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD |
title_fullStr | HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD |
title_full_unstemmed | HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD |
title_short | HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD |
title_sort | hgg-32. durable response to mtor inhibitor after failing checkpoint inhibitors in ultra-hypermutated high grade glioma in context of cmmrd |
topic | High Grade Glioma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165311/ http://dx.doi.org/10.1093/neuonc/noac079.247 |
work_keys_str_mv | AT hegdekriti hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT dahlchristine hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT depanisarita hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT hargravedarren hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT oostveenminou hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT aguirregomezcortafernando hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT jeelaniowase hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT aquilinakristian hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT gainsjenny hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT chingyen hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT jacuesthomas hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT merveashirwad hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT chalkerjane hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT addydilys hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT ahmedsairaw hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT yasinshireen hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT mankadkshitij hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT carneyolivia hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT sudhakarsniya hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT darcofelice hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT loebelulrike hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd AT jorgensenmette hgg32durableresponsetomtorinhibitorafterfailingcheckpointinhibitorsinultrahypermutatedhighgradegliomaincontextofcmmrd |